Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1072 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ORIGINAL ARTICLE Table of Contents   
Year : 2005  |  Volume : 16  |  Issue : 2  |  Page : 146-153
Beneficial Effects of Maintenance Intravenous Iron Saccharate in Hemodialysis Patients

Department of Internal Medicine, King Fahd Hospital of the University, Alkhobar, Saudi Arabia

Correspondence Address:
Samir H Al-Mueilo
Department of Nephrology, King Fahd Hospital of the University, P.O. Box 40154, Alkhobar 31952
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 18202490

Rights and PermissionsRights and Permissions

We evaluated in this study the effects of regular use of maintenance intravenous (IV) iron saccharate on the hematological parameters, iron stores, and erythropoietin (EPO) requirement in a group of stable hemodialysis (HD) patients. We maintained 34 stable HD patients (14 (41.2%) males) with a mean age of 43.1 16 years (range 17-69) and mean duration of HD of 39.3 34.5 months on EPO. We also added 50-100 mg IV iron saccharate every week during a 6-month period from May-October, 1999. At entry, 18 (47.1%) patients required loading doses of IV iron saccharate. We compared the results at entry with those at six months. The mean hemoglobin increased significantly from 97 10 to 117 20 g/l, (p<0.0001), serum ferritin increased significantly from a mean of 160 224 to 377 216 ng/ml, (p<0.0001), transferrin saturation increased from 21 1.9 to 28 8 %, (p= .0002), EPO dose decreased significantly from a mean weekly dose of 8800 3200 to 5500 3000 units (p=0.002). The cost saving analysis suggested an annual savings of 6448 Saudi Riyals (1719 US $) per patient attributable to reduction in the administered EPO dose. We conclude that IV iron saccharate use to replenish and maintain iron stores in stable EPO treated HD patients is safe and effective. It results in achieving target hemoglobin with significantly lower doses of EPO.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded275    
    Comments [Add]    

Recommend this journal